Furthermore, in an in vivo asthma model, TRPV1 antagonist, N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), attenuated the coughing induced by allergens [136]. The gene discussed is TRPV1; the disease is asthma.